• Jan
• 2022

NATCO Global

NATCO completes acquisition of Dash Pharmaceuticals LLC

• Dec
• 2021

NATCO Global

NATCO receives approval for a drug for the treatment of Covid-19 in India

• Dec
• 2021

NATCO Global

NATCO proposes to acquire Dash Pharmaceuticals LLC

• Nov
• 2021

NATCO Global

NATCO launches Tipanat tablets in India, for the treatment of advanced colorectal and gastric cancer

• Oct
• 2021

NATCO Global

NATCO announces launch of its 10mg strength for Everolimus Tablets (generic for Afinitor^®) in the US market

• Aug
• 2021

NATCO Global

NATCO transfers Lenalidomide ANDA to Arrow

• Jun
• 2021

NATCO Global

NATCO receives approval for Carfilzomib Vials ANDA (generic for KYPROLIS^® ) in the US market

• May
• 2021

NATCO Global

NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA^®) ANDA in the US market

• May
• 2021

NATCO Global

NATCO receives USFDA approval for Lenalidomide Capsules

• May
• 2021

NATCO Global

NATCO starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment

• May
• 2021

NATCO Global

NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India

• May
• 2021

NATCO Global

NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

• Apr
• 2021

NATCO Global

NATCO seeks Emergency approval of Molnupiravir capsules for Covid-19 treatment

• Mar
• 2021

NATCO Global

NATCO receives final approval for Everolimus tablets (generic for Afinitor^® ) for the US market

• Feb
• 2021

NATCO Global

NATCO launches Brivaracetam tablets, in India, for treatment of epilepsy

• Jan
• 2021

NATCO Global

NATCO receives final approval for Everolimus tablets (generic for ZORTRESS9) in the US market